Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Clinical Impact of Glucagon-Like Peptide-1 Receptor Analogs on the Complications of Obesity

Yazıcı D., Yapıcı Eser H., Kıyıcı S., Sancak S., Sezer H., Uygur M.

Clinical Trial on Osteoarthritis, published in Obes Facts (2023) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Obes Facts (2023)
Reported sample size
—
Source database
Europe PMC
PMID
36349778
PMCID
PMC10028372
DOI
10.1159/000526808
Citations
13

Abstract (original English)

Background Obesity is a chronic disease associated with increased morbidity and mortality due to its complications. The aims of obesity treatment are primarily to accomplish weight loss, and prevention or treatment of its complications. Lifestyle changes along with behavioral therapy constitute the first-line treatment of obesity followed by pharmacotherapy. Glucagon-like peptide receptor analogs (GLP-1 RAs) are among the approved pharmacotherapy options. Their central effect on suppressing appetite results in considerable weight loss. However, their effect on the complications of obesity has not been very well recognized. This review aims to analyze the effects of GLP-1 RAs on the complications of obesity, as diabetes mellitus, hypertension, nonalcoholic steatohepatitis (NASH), cardiovascular diseases, polycystic ovary syndrome, infertility, obstructive sleep apnea (OSA), osteoarthritis, cancer and central nervous system problems. Summary Data from preclinical studies and clinical trials have been thoroughly evaluated. Effects regarding the complications as far as the scope of this review have covered can be summarized as blood glucose lowering, blood pressure lowering, resolution of NASH, improving major cardiovascular events, improving fertility and sex hormone levels, and improvement in OSA symptoms and in cognitive scores. Although the mechanisms are not fully elucidated,

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
HumansDiabetes Mellitus, Type 2ObesityWeight LossHypoglycemic AgentsFemaleGlucagon-Like Peptide 1Non-alcoholic Fatty Liver DiseaseGlucagon-Like Peptide-1 Receptor

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research